Comparison of Enzyme-Linked Immunosorbent Assay and Chemiluminescence Immunoassay for Thyroid Stimulating Hormone Analysis in Tertiary Care Hospital Lahore

Nusrat Alavi, Aneela Khawaja, Maliha Asif, Asma Ejaz, Abeer, Faiqa Arshad

ABSTRACT

Objective: To compare enzyme-linked immunosorbent assay and Chemiluminescence immunoassay for thyroid stimulating hormone analysis in human serum.

Methodology: This cross-sectional study conducted from 17th March till 13th June. In Punjab Rangers Teaching Hospital, Lahore after approval from Institutional Review Board. Random samples from both genders, between 18-70 years of age were included. Haemolysed, lipemic or icteric specimens were excluded. The sera were assayed for thyroid stimulating hormone (TSH) by enzyme-linked immunosorbent assay (ELISA) and Chemiluminescence immunoassay (CLIA). Data was analyzed by SPSS 24.

Results: A total of one hundred and ninety-eight serum samples were processed by ELISA and CLIA in all the samples, with more females as compared to males (1:1.3). ELISA technique identified 134 subjects as Euthyroid, 40 Hypothyroid and 24 Hyperthyroid, while 122 Euthyroid, 48 hypothyroid and 28 hyperthyroid subjects by CLIA. Thyroid stimulating hormone (TSH) levels reference range was taken 0.4-4.5mU/L according to American Thyroid Association. Mean ± SD of TSH was 1.45 ± 0.79; 12.27 ± 11.03 and 0.23 ± 0.17 mU/L respectively by ELISA whereas CLIA indicated Mean ± SD to be 1.93 ± 0.936, 16.04 ± 14.68 and 0.393 ± 0.375 mU/L respectively for Euthyroid, hypothyroid and hyperthyroid. Correlation of coefficient (R² =0.89) was found significantly positive between both methods. There was a significant difference in hypothyroid and Euthyroid groups.

Conclusion: TSH assay by CLIA has shown a wider range of functionality, throughout and borderline cases were identified better as compared to ELISA. Turn-around-time (TAT) decreased, physician satisfaction increased and indirectly benefitting patient treatment and prognosis.

KEYWORDS: Chemiluminescence Immunoassay, Enzyme-Linked Immunosorbent Assay, Thyroid Stimulating Hormone.

INTRODUCTION

Thyroid hormones critically regulate the growth and metabolic key pathways of different organs as well as energy homeostasis. Worldwide, 300 million people suffer from abnormal thyroid functioning. The most prevalent abnormality of it is the elevation of thyroid-stimulating hormone labelled as Hypothyroidism, while Hyperthyroidism, showing decreased levels of TSH, is less common.¹ The modern advancement in technology has categorized the enzyme linked immunosorbent assay into 3rd generation assay. TSH monitoring by enzyme-linked immunosorbent assay (ELISA) in very low and very high level of frank hyperthyroidism and hypothyroidism is very beneficial in grouping subjects according to expression of TSH level.² ELISA is a popular analytic procedure that applies a solid stage enzyme immunoassay (EIA) to identify the presence of a specific element, usually an antigen, in a serum sample. In ELISA, antigens from the test specimen adjoined to a surface are treated with specific antibody; and enzyme substrate is added as a final step. End point reaction is color change in the substrate producing a detectable signal.³ Keeping in mind the benefits, of 4th generation assays,

Dr. Nusrat Alavi MBBS, M Phil
Associate Professor of Pathology
Rahbar Medical & Dental College, LHR

Dr. Aneela Khawaja MBBS, M Phil
Assistant Professor of Pathology
Rahbar Medical & Dental College, LHR

Dr. Maliha Asif MBBS, MPhil
Assistant Professor of Pathology
Rahbar Medical & Dental College, LHR

Dr. Asma Ejaz MBBS, MPhil
Assistant Professor of Pathology
Rahbar Medical & Dental College, LHR

Dr. Abeer MBBS, FCPS
Assistant Professor of Pathology
Rahbar Medical & Dental College, LHR

Dr. Faiqa Arshad MPhil, PhD Scholar,
Assistant Professor of Pathology,
Gujranwala Medical College, Gujranwala

Correspondence:
Dr. Nusrat Alavi
Email: nusratpinky@hotmail.com
Chemiluminescence immunoassay (CLIA) is widely used as a reliable, sensitive, specific, automated method which measures the immune complexes formed as a result of antigen-antibody reaction by using labelled antibodies. Substrate was added to these intact immune complexes producing light signal. The intensity of light (measured as Reactive Light Units, RLU) helps to quantify the labelled complexes. This assay significantly promotes detection of sub-minimal level of active substances in clinical diagnosis and treatment prognosis.\(^3\) In third world countries, there is a lack of reliable comparative searches between both techniques. The patients were undergoing over or under treatment and have to bear the brunt of discrepant results produced by different techniques.\(^5,6\)

The Primary aim of our study is to compare values of TSH assessed by both enzyme-linked immunosorbent assay and Chemiluminescence immunoassay in a tertiary care setting.

**METHODOLOGY**

This cross-sectional study was conducted in Pathology laboratory at Punjab Rangers Teaching Hospital, Lahore from 17\(^{th}\) March till 13\(^{th}\) June 2021. After taking ethical approval from Institutional Review Board with IRB Reference number 07/2021, A total of 198 whole blood samples of both genders, between 18-70 years of age were selected randomly and included in the study. Haemolysed, lipemic and icteric specimens were excluded from the study. Blood collected in serum separator tubes was centrifuged at 2500 rpm for 15 minutes at room temperature to obtain serum. The separated serum was aliquoted in 2 fresh micro-centrifuged tubes and stored at -20°C. Samples were tested simultaneously for TSH by both ELISA and CLIA techniques. Both methods were calibrated and controls were run.\(^6\)

Reference range to categorize the patients with thyroid disease was 0.4-4.5mU/L.

The quantitative measurement of TSH was done by ELISA and CLIA. Monoclonal antibodies coated on ELISA strips were directed against serum TSH, which reacts with the two antibodies simultaneously. This sandwich complex is immobilized to the well, and incubated for an hour and excess antibodies are removed by washing the wells. After 15 minutes, stop solution was added and the end product of colored solution was measured by ELISA reader set at 450nm.\(^7\) The standard for CLIA technique works as sandwich technique. Its principle is to employ monoclonal antibodies specifically directed against human TSH. Antibodies labelled with ruthenium complex, which consists of chimeric construct from human and mouse specific components. This test was performed on the fully automated Roche cobase 411 analyzer using CLIA, instructions of training manual were carefully followed. Eighty six tests /hour were performed. The total duration of assay was eighteen minutes. Two-point calibration curve and master curve presented through the reagent barcode or e-barcode particularly supports the outcomes.

**Statistical analysis:** Data was analyzed by SPSS 24.0. Continuous variables were expressed as mean ± SD. Mean TSH was compared by independent T-test. P-value ≤ 0.05 was considered as significant. Coefficient of correlation was applied between ELISA and CLIA for euthyroid, hypothyroid and hyperthyroid TSH levels.

**RESULTS**

A total of one hundred and ninety-eight serum samples were processed. Table 1 shows comparison of TSH status by ELISA and CLIA in all the samples, with more females as compared to males (1:1.3). TSH assay by both techniques identified 134 and 122 subjects as Euthyroid by ELISA and CLIA, respectively. Similarly, ELISA identified 40 subjects as hypothyroid while 48 were found hypothyroid by CLIA, on the basis of reference value 0.4-4.5mU/L. The difference was highly significant in hypothyroid and Euthyroid subjects.

**Table 1:** Comparison of Thyroid Stimulating hormone by ELISA and CLIA (N=198).

| TSH Reference 0.4-4.5mU/L | ELISA | CLIA |
|---------------------------|-------|------|
| N 198                     |       |      |
| Mean±SD                  | Mean±SD | p-value |
| Hypothyroid               | 40    | 48   | <.0005 |
| 12.27±11.03               | 16.04±14.68 |
| Euthyroid*                | 134   | 122  | <.005  |
| 1.45±0.79                 | 1.93±0.93 |
| Hyperthyroid              | 24    | 28   | 0.127  |
| 0.23±0.17                 | 0.39±0.375 |

TSH= Thyroid Stimulating Hormone; ELISA= Enzyme Linked Immunosorbent Assay; CLIA= Chemiluminescence immunoassay. Euthyroid* Range was identified in 134 and 122 subjects respectively, by ELISA and CLIA. P-value ≤ 0.05 taken as significant.

In Table 2, the difference of mean cases with similar diagnosis is shown that 37 hypothyroid samples when tested by ELISA fall in 4.8-44mU/L, while these same samples by CLIA gave results from 4.58-38mU/L. Shifting of 24 subjects from (134, in Table 1) Euthyroid by ELISA to either hypothyroid or hyperthyroid groups; and 12 subjects from (122, in Table 1) Euthyroid by CLIA to other groups.
Similarly, the difference of hyperthyroid samples (22, as in Table 2) was shown by 2 subjects and 6 subjects by ELISA (24 as given in Table 1) and CLIA (28 as in Table 1), respectively. P-value was highly significant in hypothyroid and Euthyroid subjects, while insignificant in hyperthyroid samples. Correlation of coefficient ($R^2=0.89$) was positive between both methods (Figure 1).

| TSH Reference 0.4-4.5mU/L | ELISA* | Mean ± SD | CLIA* | Mean ± SD |
|---------------------------|--------|-----------|-------|-----------|
| Hypothyroid 37            | 4.8-44 | 11.9± 10.64 | 4.58-38 | 15.11± 14.73 |
| Euthyroid 110             | 0.4-3.7 | 1.44±0.79 | 0.56-4.2 | 1.90±0.92 |
| Hyperthyroid 22           | <0.01-36 | 0.174±0.17 | <0.01-39 | 0.145±0.12 |

ELISA* and CLIA* range of TSH level in N=169 subject

**DISCUSSION**

Thyroid disorders are the commonest endocrine disorders throughout the world including Pakistan.7 For diagnosis and management of thyroid diseases, thyroid function test is the most frequently advised endocrine investigation.7 The guiding principles of American Thyroid Association and American Association of Clinical Endocrinologists serum TSH measurements has recommended as a primary screening test to diagnose most types of hypothyroidism & hyperthyroidism.8 TSH secretion is exquisitely sensitive to minor increase, as well as decreases in serum free $T_4$. Abnormal TSH levels are detected earlier during developing the course of hypothyroidism and hyperthyroidism even before free $T_4$ abnormalities become detectable.8,9 Although thyroid disorders are not a life threatening disorder, but if it is not diagnosed timely and remained untreated, it may develop into life threatening disorders like cancer. Moreover, thyroid gland malfunctioning will greatly affect various functions of many other body parts which depend on the hormonal secretion of thyroid hormones for performing their normal functions.10

In our study the patients were divided into three groups according to serum TSH levels i.e., euthyroid, hypothyroid and hyperthyroid. Our results indicate significant difference in TSH levels measured by ELISA and CLIA for euthyroid, hypothyroid subjects, however the difference was insignificant by both methods for hyperthyroid subjects. Same results are documented within Pakistan by Ejaz et al and internationally by Santosh et al.10,3

In our study, thyroid diseases were found to be more prevalent (56%) in females compared to males. Similar findings are reported locally by Naz et al and Shah et al11,12 and internationally by Paczkowska et al.13 In our study, 169 subjects gave same results by both methods with highly significant difference in hypothyroid and Euthyroid subjects. Statistically, all the data was analyzed for coefficient of correlation and it displayed a significant coefficient of correlation ($R^2=0.8598$) as documented locally by Naz et al and foreign researcher Hamed et al.11,14

In present study two methods, ELISA and CLIA were compared for determination of TSH. The comparison of both methods shows CLIA exhibit better and higher sensitivity as revealed by Higgins et al, with wider range (0.005-100.0mU/L) as compared to ELISA (0.09-40.0 mU/L).15 The reason for this discrepancy could be technique based, errors in pipetting and washing step, fluctuation in instrument handling. Other disadvantages of ELISA are its laborious techniques with high incidence of false positive and negative results and antibody instability as shown in research by Pramila et al.16 In our set up, the clinician’s feedback was considered regarding discrepancy of results and delayed turnaround time prompted the decision to up-grade the diagnostics with advanced 4th generation autoanalyzer. Present study clearly indicates that Chemiluminescence has better analytical sensitivity than ELISA, which can differentiate between normal and subnormal TSH levels as shown by the work done in our region by Shah et al and in neighboring countries by Higgins et al and Jiang et al.17,18,15 Further studies on a broader scale will yield better results for understanding the importance of diagnostic accuracy of various techniques for thyroid function tests for accurate diagnoses of thyroid disorders.

**Figure 1:** The coefficient of correlation between ELISA and CLIA (n=198)
CONCLUSION

TSH assay by CLIA has shown a wider range of functionality, throughout and borderline cases were identified better as compared to ELISA. Turn-around-time (TAT) decreased, physician satisfaction increased and indirectly benefitting patient treatment and prognosis.

Conflict Of Interest: None

Funding Source: Whole project was self-funded.

Acknowledgment: Jamil Ahmad, Sharjeel Ahmad are highly acknowledged for compiling data and results compilation.

REFERENCES

1. Taylor PN, Elgar V, Muller I, Scholz A, Dayan C, Okosieme O. Combination thyroid hormone replacement: knowns and unknowns. Front Endocrinol 2019, 22 (10): 706 doi: 10.3389/fendo.2019.00706
2. Silvestre RA Lafuente AA, Jiménez-Mendiguchía L, García-Canó A, López RR, García-Izquierdo B, et al. Comparison of three methods for determining anti-thyrotropin receptor antibodies (TRAb) for diagnosis of Graves’ disease: a clinical validation. Adv Lab Med 2021; 2(2): 221-227. doi.org/10.1515/almed-2021-0015.
3. Santhosh V, Gurulakshmi G, Khadeja A, Gomathi M. The Diurnal Variation of Thyroid Hormones in Individuals Attending Tertiary Care Hospital, Kanchipuram District, Biomedical PharmacoJ.2020;13(4):17291735. https://dx.doi.org/10.13005/bpj/2.047.
4. Xiao Q, Xu C. Research progress on chemiluminescence immunoassay combined with novel technologies. TrAC Trends AnalyticChem.2020;124:115780https://doi.org/10.1016/j.trac.2019.115780
5. Mirjanic-Azaric B, Jerin A, Radic Z. Thyroid stimulating hormone values of clinical decisions of hypothyroidism measurement by three different automated immunoassays. Scandinavian J Clin laboratory Invest.2020;80(2):151-155.
6. Sultana I, Alam JM, Ali HH, Noureen S. Reproducibility, Repeatability and Precision analysis of Thyroid function tests (TFT) on two, separately operated LRS integrated Roche Cobas e411 iECL analyzers. Chem Res J. 2020; 5(2):151-156
7. Yousaf M, Shah J, Jan MR. Frequency of Thyroid Dysfunctions in General Population of Peshawar city and its Association with Serum Alanine Transaminase Level. Isra Med J. 2017;9(2):84-87
8. Garber JR, Cobin RH,GharibH,Hennessey JV, Klein I, Mechanick J, et al. Thyroid Dysfunction: Hypothyroidism, Thyrotoxicosis, and Thyroid Function TestsFree AccessClinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. ThyroidVol. 2012 :22(12):1200-1235.https://doi.org /10.1089/thy.2012.0205
9. Attuallah S, Haq BS,Mairma Muska M. Thyroid dysfunction in Khyber Pakhunkhwa, Pakistan. Pak J Med Sci. 2016; 32(1): 111–115. doi:10.12669/pjms.321.8476.
10. Ejaz M, Kumar P, Thakur M, Bachani P, Naz S, Lal K, Shahid W, Shahid S, Jahangir M, Rizwan A. Comparison of Lipid Profile in Patients With and Without Subclinical Hypothyroidism. Cureus.2021;13(8)e17301.DOI: 10.7759/cureus.17301.
11. Naz N, Rizvi S, Sadiq Z. Assessment of thyroid hormone levels and thyroid disorders: A case study from Gujranwala, Pakistan. Pak J Pharmaceutical Sci. 2017; 30(4):1245-49.
12. Shah N, Urami TJ, Shah NA, Raza HM. Prevalence and Manifestations of Hypothyroidism among Population of Hyderabad, Sindh, Pakistan. Pure Appl Biol (PAB). 2021; 10(3):668-675. http://dx.doi.org/10.19045/hspab.2021.100076.
13. Paczkowska K, Otlewka A, Loska O, Kolačkov K, Bolanowski M, Daroszewski J. Laboratory interference in the thyroid function test. Endocrinol Pol.2020;71(6):55160 doi:10.5603/EP.a2020.0079.
14. Hamed A, Nurm N, Alhalabi N, Tayfour R, Latifeh Y. Prevalence of depression in group of hypothyroid patients and its relationship with the level of hypothyroidism. Biomed Res. 2021; 32(2):1-7.
15. Jiang L, Du J, Wu W, Fang J, Wang J, Ding J. Sex differences in subclinical hypothyroidism and associations with metabolic risk factors: a health examination-based study in mainland China. BMCEndocrDisord.2020;20(1):18.https://doi.org/10.1186/s12902-020-00586-5.
16. Pramila K, Gopinath P, Shanthi K M, Divya M. Analytical sensitivity of TSH assays by ELISA and ELFA. Nation J Basic Med Sci. 2016; 6 (4): 157-162.
17. Shah N, Urami TJ, Shah NA, Raza HM. 17. Assessment of association between hypothyroidism and hypertension among females of Hyderabad, Sindh, Pakistan. Pure Appl Biol (PAB). 2021; 10(3):744-50.
18. Higgins V, Patel K, Kulasingam V, Beriault DR, Rutledge AC, Selvaratham R. Analytical performance evaluation of thyroid-stimulating hormone receptor antibody (TRAb) immunoassays. Clin Biochem.2020;86:5660 https://doi.org/10.1016/j.clinbiochem.2020.08.007.

Authors’ contribution:

Dr. Nusrat Alavi
Conception of study design, acquisition, analysis and interpretation of data.

Dr. Aneela Khawaja
Drafting and methodology, data interpretation.

Dr. Malika Asif
Drafting of intellectual content.

Dr. Asma Ejaz
Drafting of the research work and critical revision.

Dr. Abeer Sheikh
Analysis and interpretation of data for work.

Dr. Faiza Arshad
Analysis, acquisition and interpretation of data.

All authors participated in study design and writing manuscript and agree to be accountable for accuracy, integrity of all aspects of the work.

Received: 17 Aug 2021,
Revised received: 10 Oct 2021,
Accepted: 12 Oct 2021